Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2022 Results Conference Call November 8, 2022 8:00 AM ET

Company Participants

Stephanie Ascher - Stern Investor Relations

Bryan Stuart - President and Chief Executive Officer

Esther Rajavelu - CFO

Paul Bruno - Senior Vice President, Corporate Development

Conference Call Participants

Dae Gon Ha - Stifel

Judah Frommer - Credit Suisse

Matt Biegler - Oppenheimer

Joseph Schwartz - SVB Leerink

Operator

Good morning, and welcome to Fulcrum Therapeutics Third Quarter 2022 Conference Call [Operator Instructions].

I would now like to turn the call over to Stephanie Ascher from Stern Investor Relations. Please proceed.

Stephanie Ascher

Thank you, Carolyn. Good morning, and welcome to the Fulcrum Therapeutics conference call. Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans, clinical development time lines and financial projections. While these forward-looking statements represent our views as of today, they should not be relied upon as representing our views in the future. We may update these statements in the future, but we are not taking on an obligation to do so. Please refer to our most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with our business. With me on today's call are Bryan Stuart, President and Chief Executive Officer; and Esther Rajavelu, our CFO. Paul Bruno, our Senior Vice President of Corporate Development, will also be available for Q&A. Let me quickly run through this morning's agenda. Bryan will begin the call with a corporate overview and key updates, including on our clinical programs. Esther will cover our financials, and Bryan will open the call for Q&A.

With that, it's my pleasure to turn the call over to Bryan.

Bryan Stuart

Thanks, Stephanie. Good morning, everyone, and thanks for joining us today. At Fulcrum, our mission is to treat the root cause of genetically defined rare diseases, and this quarter, we have continued to make progress towards bringing transformative therapies to patients. Currently, we have two clinical programs with the potential to dramatically transform the treatment paradigm in sickle cell disease and FSHD. We are committed to moving both programs through the development and regulatory process as rapidly as possible to address the significant unmet needs that we know exist in these patient populations. We are also continuing to invest in our research engine and expect to file our next IND in 2023. At our last update, we announced a strategic realignment to prioritize our internal investments in our 2 key value-driving clinical programs intended for the treatment of FSHD and SCD. This extended our runway into mid-2024 at that time. In August, we closed an underwritten public offering that resulted in net proceeds of approximately $81 million that has extended our runway further, and we are in a strong cash position that enables us to continue to execute on our mission. Esther will provide details on our financials later in the call.